Exelixis CMO Vicki Goodman departs effective August 23, 2023; entitled to severance benefits

EXELIXIS, INC.

Vicki L. Goodman, EVP Product Development & Medical Affairs and CMO, concludes service effective August 23, 2023.
Goodman is eligible for payments under Exelixis' Change in Control and Severance Benefit Plan.
No successor or interim CMO has been named in this filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Vicki L. Goodman

Chief Medical Officer

EXEL · EXELIXIS, INC.

Effective: 2023-08-23
Filed: August 23, 2023, 7:59 PM ET

Effective August 23, 2023, Vicki L. Goodman, M.D., will conclude her service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer of Exelixis, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Vicki L. Goodman departed as Chief Medical Officer at EXELIXIS, INC..

Action: departed
Role: Chief Medical Officer

Exact text from the filing

Effective August 23, 2023, Vicki L. Goodman, M.D., will conclude her service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer of Exelixis, Inc.

View on SEC.gov

EXELIXIS, INC. filing history →

Source: SEC EDGAR

accession 0000939767-23-000093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.